Six months of PAP treatment decreased monomeric/dimeric sulfinic–sulfonic (overoxidized) forms of PRDX2 in OSA RBC while it increased sulfinic–sulfonic decameric forms of this protein, which are described as having a chaperone protective function [10]. Here, PRDX2 is linked to obstructive sleep apnea syndrome.